Web Results

Nivolumab versus Docetaxel in Advanced Squamous-Cell Non ...

www.nejm.org/doi/full/10.1056/NEJMoa1504627?fromsource=nelm& - t=articleTop

May 31, 2015 ... Julie Brahmer, M.D., Karen L. Reckamp, M.D., Paul Baas, M.D., Lucio ... (Funded by Bristol-Myers Squibb; CheckMate 017 ClinicalTrials.gov ...

Preclinical Characterization of BMS-791325, an Allosteric Inhibitor of ...

www.ncbi.nlm.nih.gov/pmc/articles/PMC4068470/

Julie A. Lemm, <sup>corresponding author</sup> ... BMS-791325 is an allosteric inhibitor that binds to thumb site 1 of the hepatitis C virus (HCV) NS5B RNA-dependent RNA polymerase. .... were synthesized by Bristol-Myers Squibb, as were HCV reference inhibitors ..... Substitutions at NS5B codon 495 were also seen by Pelosi et al.

Predictors of sustained reduction in energy and fat intake in the ...

www.ncbi.nlm.nih.gov/pmc/articles/PMC3962017/

Knowler et al. found that in the DPP, session attendance was associated with older age, which may have contributed to long-term weight loss success. ... Bristol-Myers Squibb and Parke-Davis provided additional funding and .... Julie Bamdad, MS .... Ramachandran A, Snehalatha C, Mary S, Mukesh B, Bhaskar AD , Vijay V.

Adjuvant Erlotinib Versus Placebo in Patients With Stage IB-IIIA Non ...

jco.ascopubs.org/content/early/2015/09/17/JCO.2015.61.8918.full

Aug 31, 2015 ... ... MD, University of California, Davis, Comprehensive Cancer Center, 4501 X St, ... DFS favored erlotinib (median, 46.4 v 28.5 months; hazard ratio, 0.61; 95% CI, ..... Boehringer Ingelheim, Merck, Merck Serono, Bristol-Myers Squibb, ... Julie D. Horan ... Strauss GM,; Herndon JE 2nd,; Maddaus MA,; et al.

Associations between Potentially Modifiable Risk Factors ... - PLOS

journals.plos.org/plosmedicine/article/asset?id=10.1371/journal.pmed.1001841.PDF

Jun 16, 2015 ... al nature of these associations using Mendelian randomization (MR). Methods and Findings ..... Pharma AG, Bristol-Myers Squibb, Eisai Global.

Common variants at MS4A4/MS4A6E, CD2AP, CD33 and EPHA1 ...

www.nature.com/ng/journal/v43/n5/abs/ng.801.html

Carrasquillo, M.M. et al. ..... Department of Neurology, University of Alabama at Birmingham, Birmingham, ... Jeffrey L Cummings,; John M Ringman &; Harry V Vinters ... Laboratory Medicine, University of California Davis, Sacramento, California, .... Inc. M.R.F. receives research funding from Bristol-Myers Squibb Company, ...

Full Text (PDF) - Proceedings of the National Academy of Sciences

www.pnas.org/content/112/30/E4085.full.pdf

Jul 13, 2015 ... Cilag, and Bristol-Myers Squibb and speaker's fees from ... activation in the ventral striatum (VS) during reward anticipation. ... reduced ethanol sensitivity in ics mutants was not caused by al- ... Ojelade et al. ...... McGuire SE, Le PT, Osborn AJ, Matsumoto K, Davis RL (2003) Spatiotemporal rescue of.

Does a GLP-1 receptor agonist change glucose tolerance in patients ...

bmjopen.bmj.com/content/4/3/e004227.full

Mar 25, 2014 ... Correspondence to Dr Julie Rask Larsen; dr.rask@gmail.com .... In a study by Astrup et al,7 16 of 90 patients (17.8%) in the liraglutide 1.8 mg group withdrew over the 20-week trial period. .... as well as grants from Bristol-Myers Squibb, Janssen/J&J and Otsuka. .... Hermes E,; Nasrallah H,; Davis V,; et al.

Effects of p38 Mitogen-Activated Protein Kinase Inhibition on ...

www.sciencedirect.com/science/article/pii/S1936878X12005281

Sep 10, 2012 ... Editorial assistance was provided by Julie Taylor (funded by GlaxoSmithKline). .... 21; Z.A. Fayad, V. Mani, M. Woodward, et al. ... Drs. Sarov-Blat, Cai, Lepore, Davis, Willette, and Sprecher are employees ... Dr. Tawakol has received research grants from Bristol-Myers Squibb, GlaxoSmithKline, Merck & Co.

Outcomes by Sex Following Treatment Initiation With Atazanavir ...

cid.oxfordjournals.org/content/58/4/555.full

Nov 18, 2013 ... B, Subjects on ABC/3TC, comparing women vs men. ..... We also thank Abbott Laboratories, Bristol-Myers Squibb, Gilead Inc, and GlaxoSmithKline for providing ... Richard B. Pollard, MD, and Abimbola Olusanya, NP, University of California, Davis Medical Center ... Thompson MA,; Aberg JA,; Hoy JF,; et al.

More Info

Effect of Cognitive Therapy With Antidepressant Medications vs - NCBI

www.ncbi.nlm.nih.gov

Combined treatment enhanced the rate of recovery vs treatment with ADM alone ..... Julie Jacobs, PhD, Cory P. Newman, PhD, and Rita Ryan, PhD (University of ... reports being a consultant to Bristol-Myers Squibb, Cerecor, Inc, Cyberonics, .... Hollon SD, DeRubeis RJ, Shelton RC, et al. ... Beck AT, Freeman A, Davis DD.

JAMA Network | JAMA | Three- vs Four-Drug Antiretroviral Regimens ...

jama.jamanetwork.com

Aug 16, 2006 ... ObjectiveTo compare the safety/efficacy of 3-drug vs 4-drug regimens for initial treatment of HIV-1 infection. ... patients could substitute stavudine (Zerit, Bristol- Myers Squibb) for zidovudine, .... *Details reported in Gulick et al. ...... Jr, MD ( University of Minnesota); Paula Potter, RN, BSN, Julie Hoffman, RN, ...

Identification of Cancer Care and Protocol Characteristics ...

jco.ascopubs.org

Sep 20, 2008 ... Lastly, Mills et al conducted a systematic review to assess barriers at the patient level. ..... Consultant or Advisory Role: Julie Lemieux, Abraxis (C), Bristol-Myers Squibb (C), ... Gross CP, Murthy V, Li Y, et al: Cancer trial enrollment after ... Davis SW, Nealon EO, Stone JC: Evaluation of the national cancer ...